Wigen Biomedicine Technology (Shanghai) Co. Ltd. has described GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.

TYK Medicines Inc. and Zhejiang Tongyuankang Pharmaceutical Co. Ltd. have identified tyrosine-protein phosphatase non-receptor type 11 (PTPN11) inhibitors reported to be useful for the treatment of cancer and LEOPARD and Noonan syndrome.

Dana-Farber Cancer Institute Inc. has disclosed proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase-binding moiety coupled to an anaplastic lymphoma kinase (ALK)-targeting moiety through a linker reported to be useful for the treatment of cancer.

Novartis AG has patented sphingosine 1-phosphate S1P3 receptor antagonists reported to be useful for the treatment of lung inflammation.

BioWorld MedTech presents Patent Highlights, an excerpt of the most important med-tech patents from this week's Cortellis Patents Gazette.

Tecnimede-Sociedade Tecnico-Medicinal SA has described heterocyclic compounds reported to be useful for the treatment of tuberculosis.

Astrazeneca AB and Mitsubishi Tanabe Pharma Corp. have divulged NLRP3 inflammasome inhibitors reported to be useful for the treatment of liver, autoimmune and inflammatory bowel disease, inflammation, respiratory, cardiovascular and renal disorders.

Janssen Pharmaceutica NV has identified 5-oxo-pyrido[2,3-d]pyridazin-6(5h)-yl acetamides acting as NLRP3 inflammasome inhibitors reported to be useful for the treatment of cancer, viral hepatitis, diabetes, immunological, inflammatory, neurological, cardiovascular and metabolic disorders.

Medshine Discovery Inc. has synthesized dimethyl-substituted thiazololactam compounds acting as mitogen-activated protein kinase 3 (MAPK3; ERK1) and/or (MAPK1; ERK2) inhibitors reported to be useful for the treatment of cancer.